CureVac’s Independent Journey Concludes Following BioNTech Acquisition

A definitive chapter has closed for investors in CureVac. The German biotech firm’s standalone history as a publicly traded company has reached its conclusion, marking the end of a period characterized by high hopes, subsequent setbacks, and complex patent litigation. The company’s shares have now been permanently removed from listing, with all future operations concerning its mRNA technology and intellectual property to be managed under the umbrella of its industry peer, BioNTech.

The market responded immediately to the finalization of the takeover. Trading in CureVac stock was halted on the Nasdaq Global Market as of today, rendering any further buy or sell orders through the exchange impossible. The ticker symbol Read more...